Objectives: The chemokine receptor antagonists maraviroc and vicriviroc and the integrase inhibitors elvitegravir and raltegravir are novel antiretroviral agents for the treatment of HIV-1 infections. ATP-binding cassette (ABC) transporters as modulators of the effectiveness and safety of therapy can mediate viral resistance and drug -drug interactions. To expand knowledge on drug-drug interactions of these antiretrovirals we investigated whether these compounds are substrates, inhibitors or inducers of important ABC transporters.
Introduction
Highly active antiretroviral therapy (HAART), consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) or boosted protease inhibitor (PI) individualized for the patient, is the recommended first-line treatment of HIV-1 infections 1 and provides sustained control of virus replication in many patients. 2 Treatment failure, however, can occur for clinical, immunological and virological reasons, 3 multidrug resistance (MDR) being one of the major obstacles. New treatment options for salvage therapy are therefore of considerable importance, and several new antiretrovirals have recently been approved or are currently in clinical development. Raltegravir represents the first drug of the new class of integrase inhibitors, which target viral integrase and inhibit integration of the viral DNA copy into the DNA of host cells. 3 Raltegravir is approved for the treatment of HIV-1 infections in combination with other antiretroviral medicinal products in adult patients and represents, in addition to NRTIs, NNRTIs and PIs, a new option in therapy-naive patients. Elvitegravir is also an integrase inhibitor and is currently being tested in Phase III clinical studies. Maraviroc, the first approved drug of the class of CC chemokine receptor 5 (CCR5) antagonists, binds to the human chemokine receptor CCR5 and prevents binding of viral gp120 to co-receptor CCR5 and hence entry of the viral capsid into the host cell. 3 Maraviroc has received approval for add-on treatment of therapy-experienced adult patients infected with only CCR5-tropic HIV-1. The CCR5 antagonist vicriviroc is currently being tested in treatment-naive patients in an ongoing Phase II clinical study.
Pharmacokinetic drug -drug interactions are a critical factor for treatment response to antiretrovirals. Interactions may lower drug concentrations to subtherapeutic concentrations, 4 cause treatment failure and promote viral resistance. In contrast, interactions increasing drug exposure may augment toxicity. Main mechanisms of interaction in antiretroviral therapy involve efflux transporters, uptake transporters and the drug-metabolizing cytochrome P450 enzymes (CYPs). Crucial efflux transporters are the ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp/ABCB1), multidrug resistance-associated proteins (MRPs/ABCCs) and breast cancer resistance protein (BCRP/ABCG2), which have been identified as major sites of antiretroviral drug interactions. 5 -8 Relevant uptake transporters comprise the organic anion-transporting polypeptides/solute carrier organic anion transporter OATP1B1/SLCO1B1, OATP1B3/SLCO1B3 and OATP2A1/SLCO2A1, which have been shown to alter drug disposition and to be involved in drug -drug interactions. 9, 10 Data on interactions of elvitegravir, maraviroc, raltegravir and vicriviroc are sparse. Elvitegravir is metabolized by CYP3A enzymes and glucuronidated by UGT1A1 and UGT1A3. 11 Maraviroc is suggested to be a substrate of ABCB1 12 -14 and CYP3A4. 15 If maraviroc is given in combination with CYP3A4 inducers such as efavirenz, the maraviroc dose needs to be increased. 16 In combination with an inducer and an inhibitor of CYP3A4, such as protease inhibitors, the net effect is inhibition and dose reduction might be necessary. 16 Raltegravir is not metabolized by CYP enzymes and to date there is no evidence for relevant induction or inhibition of drug-metabolizing enzymes. 17, 18 Vicriviroc is metabolized primarily by CYP3A4 and to a small extent by CYP3A5 and CYP2C9. 19 These new antiretrovirals clearly offer a new seminal possibility for salvage therapy of HIV patients. However, thus far data on their drug -drug interaction potential are insufficient, although crucial for maximum safety and effectiveness. Indeed, little attention has been paid to the substrate characteristics of new antiretrovirals regarding ABCB1, ABCG2 and ABCCs and their potential to inhibit or induce drug transporters. We therefore assessed whether elvitegravir, raltegravir, maraviroc and vicriviroc are substrates of ABCB1, ABCG2, ABCC1, ABCC2 or ABCC3 by performing cellular resistance (proliferation) assays. Additionally, we tested their inhibitory potential for ABCB1, ABCG2 and ABCC2. Moreover, we investigated whether these antiretrovirals induce ABC transporters, OATPs/SLCOs, CYPs and the pregnane X receptor (PXR) by exposure of human adenocarcinoma LS180 cells, which are a surrogate for the major site of drug interactions and a well-established induction model.
Materials and methods

Materials
Culture media, medium supplements, DMSO, Hanks balanced salt solution (HBSS), rhodamine 123 and PBS were purchased from SigmaAldrich (Taufkirchen, Germany). Fetal calf serum (FCS) was purchased from PAA (Pasching, Austria) and Triton X-100 from Roche Applied Science (Mannheim, Germany). Crystal Violet and rifampicin were purchased from AppliChem (Darmstadt, Germany). Methanol was obtained from Roth (Karlsruhe, Germany). Cell culturing bottles were supplied by Greiner (Frickenhausen, Germany), and 96-well microtitre plates were supplied by Nunc (Wiesbaden, Germany). Collagen R was obtained from Serva (Heidelberg, Germany). Pheophorbide A (PhA) was purchased from Frontier Scientific Europe (Carnforth, UK) and calcein acetoxymethylester (calcein-AM) from Invitrogen (Karlsruhe, Germany). MK571 was purchased from Biomol Research Laboratories (Plymouth Meeting, PA, USA). RNeasy Mini-Kit was obtained from Qiagen (Hilden, Germany). Fumitremorgin C (FTC) was kindly provided by the National Cancer Institute (Rockville, USA). LY335979 (zosuquidar) was a kind gift of Eli Lilly (Bad Homburg, Germany). Elvitegravir and vicriviroc were purchased from Selleck Chemicals LLC (Houston, TX, USA). Maraviroc was kindly provided by Pfizer GmbH (Berlin, Germany) and raltegravir by Merck Sharp & Dohme GmbH (Haar, Germany).
Stock solutions of test compounds
Stock solutions of vicriviroc (10 mmol/L) and raltegravir (10 mmol/L) were prepared in sterile water. Stock solutions of maraviroc (10 mmol/L) and elvitegravir (10 mmol/L) were prepared in DMSO. The maximum concentration of DMSO was limited to concentrations that have previously been demonstrated to have no effect in the respective assay (1% in inhibition and growth inhibition assays and 0.1% in induction assays).
Cell lines
MDCKII, MDCKII-BCRP, MDCKII-MDR1, MDCKII-MRP1, MDCKII-MRP2 and MDCKII-MRP3 cells
MDCKII-BCRP cells were generated by stable transfection with human full-length wild-type cDNA and green fluorescent protein. 6 MDCKII-MDR1, MDCKII-MRP1, MDCKII-MRP2 and MDCKII-MRP3 were generated by stable transfection with the corresponding cDNA into MDCKII cells. 20, 21 Transfected cell lines were provided by Dr P. Borst (Netherlands Cancer Institute, Amsterdam, The Netherlands). The parental cell line MDCKII (available from ATCC, Manassas, VA, USA) was used as a control. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS, 2 mmol/L glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin sulphate.
LLC-PK1 and L-MDR1 cells
L-MDR1 cells, a porcine kidney epithelial cell line overexpressing the human ABCB1 gene, 22 and the corresponding parental cell line LLC-PK1 (available from ATCC, Manassas, VA, USA) as a control were used for ABCB1 inhibition assays. The L-MDR1 cell line was kindly provided by Dr A. H. Schinkel (Netherlands Cancer Institute, Division of Experimental Therapy, Amsterdam, The Netherlands). The cells were cultured under standard cell culture conditions with medium M199 supplemented with 10% FCS, 2 mmol/L glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin sulphate. 23 To maintain ABCB1 expression the culture medium for L-MDR1 was supplemented with 0.64 mmol/L vincristine. One day before the calcein assay, both cell lines were fed with vincristine-free culture medium.
P388 and P388/dx cells
The murine monocytic leukaemia cell line P388 and the corresponding doxorubicin-resistant cell line P388/dx overexpressing mdr1a/1b 24 were used for ABCB1 inhibition assays. Both cell lines were kindly provided by Dr D. Ballinari (Pharmacia & Upjohn, Milan, Italy). The cells were cultured under standard cell culture conditions with RPMI 1640 medium containing 10% FCS, 2 mmol/L glutamine, 500 mmol/L b-mercaptoethanol, 100 U/mL penicillin and 100 mg/mL streptomycin sulphate. To maintain ABCB1 expression, the culture medium for P388/dx was supplemented Novel antiretrovirals and drug transporters 803 JAC with 0.43 mmol/L doxorubicin. One day before the assay, both cell lines were fed with doxorubicin-free culture medium.
LS180 cells
The human colon adenocarcinoma cell line LS180 (available at ATCC, Manassas, VA, USA) was used for induction experiments as a surrogate for the intestine, a major site of drug interactions. 25 -27 Cells were cultured under standard cell culture conditions with DMEM supplemented with 10% FCS, 2 mmol/L glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin sulphate and 0.1 mmol/L non-essential amino acids.
Cytotoxicity assay
Maraviroc, vicriviroc, raltegravir and elvitegravir were tested for cytotoxic effects prior to ABCB1, ABCG2 and ABCC2 inhibition assays with the Cytotoxicity Detection Kit (Roche Applied Science, Mannheim, Germany), a colorimetric assay for the quantification of the activity of lactate dehydrogenase, which is released from the cytosol of damaged cells. Cytotoxicity was expressed as a percentage of the effect obtained with the positive control (1% Triton X-100). Inhibition assays were conducted with concentrations that have been shown to be non-toxic in the respective cell line.
ABCB1 inhibition assay (calcein uptake assay)
The calcein assay was used to assess ABCB1 inhibition in L-MDR1 cells and P388/dx cells. The assay was conducted and validated as described previously. 23, 28 Briefly, the assay was performed using 96-well microtitre plates. Adherent L-MDR1 cells were seeded 3 days prior to the experiment. Before the experiment, cells were washed with HBSS supplemented with 10 mmol/L HEPES (HHBSS) and preincubated for 30 min at 378C. After incubation with the test compounds for 10 min, calcein-AM was added for a further 60 min of incubation. Afterwards, uptake was stopped on ice and cells were washed twice with pre-cooled HHBSS. Cells were lysed with 1% Triton X-100 for 15 min and calcein fluorescence was measured with 485 nm excitation and 535 nm emission filters in a Fluoroskan Ascent fluorometer (Labsystems, Frankfurt, Germany). Each concentration was tested in octuplet and each experiment was performed at least in triplicate or in duplicate if no inhibition was seen. For calculation of the inhibitory effects in the calcein assay, the f2 value (concentration needed to increase baseline fluorescence by factor 2) was calculated as described and validated previously 23, 29 because some compounds did not reach plateau effects.
ABCG2 inhibition assay (PhA flow cytometry efflux assay)
The flow cytometric ABCG2 inhibition assay was performed as described and validated previously. 30 Briefly, the accumulation of the fluorescent reporter substrate PhA in the ABCG2-overexpressing cell line MDCKII-BCRP was compared with the accumulation in the control cell line MDCKII. Cells (1×10 6 ) were incubated for 30 min in RPMI medium supplemented with 2% FCS only as a negative control and in RPMI/2% FCS containing 1 mmol/L PhA. After incubation, cells were washed and subsequently incubated with RPMI/2% FCS as a negative control, with the ABCG2 inhibitor FTC as a positive control at a concentration of 10 mmol/L and with various concentrations of the test compounds. After incubation for 60 min at 378C on a rotary shaker, cells were washed and resuspended in pre-cooled PBS with 2% FCS. Intracellular PhA fluorescence was analysed in a Becton Dickinson LSR II flow cytometer with a sapphire blue laser and a 530/30 bandpass filter for green fluorescent protein and a 633 nm helium/neon laser and a 660/20 bandpass filter for PhA. In each sample, 30000 cells were analysed. Living cells were gated using forward versus side scatter. ABCG2-overexpressing MDCKII-BCRP cells were additionally gated by their green fluorescent protein signal. Quantification of inhibition was calculated as published previously. 30 Each experiment was performed at least three times on different days.
ABCC2 inhibition assay
To assess ABCC2 inhibition we used the MRP2 PREDIVEZ TM Vesicular Transport Kit (Solvo Biotechnology, Budaö rs, Hungary). The inhibitory effect of test compounds on ABCC2 was quantified by accumulation of the fluorescent reporter substrate 5(6)-carboxy-2 ′ ,7 ′ -dichlorofluorescein (CDCF) in inverted vesicular membranes containing ABCC2 transporters. The assay was conducted according to the manufacturer's instructions.
Growth inhibition assay
Many antiretroviral drugs accumulate to toxic intracellular concentrations in cell cultures at high extracellular concentrations. 31 ABC transporters are efflux transporters that influence the intracellular concentration of antiretrovirals like PIs. Changes in efflux activity of ABC transporters may alter the intracellular concentration and subsequent sensitivity of cells to antiretrovirals. We therefore used the growth inhibition assay in MDCKII cells overexpressing human ABCB1, ABCG2 and ABCC1-3 as a surrogate for intracellular concentrations and substrate characteristics of the new antiretroviral agents, as this assay has been standardized for cytostatic drugs 32 and already described for antiretroviral drugs. 33, 34 Overexpression of the corresponding transporter leads to decreased intracellular concentrations. This results in higher IC 50 values of transported antiretrovirals in transporter-overexpressing MDCKII cells compared with the IC 50 values in the MDCKII parental cell line used as a control. Antiretrovirals were tested at 10 concentrations spread over a wide range between 0.005 and 100 mmol/L for maraviroc and elvitegravir and between 0.01 and 500 mmol/L for raltegravir and vicriviroc. Concentration-response curves and IC 50 values were calculated by GraphPad Prism version 5.02 (GraphPad Software Inc., La Jolla, CA, USA) according to a sigmoid E max model. Furthermore, we used the growth inhibition assay in LS180 cells to determine optimum concentrations for the induction assay, as the concentration for induction should not have profound antiproliferative effects. The maximum concentration for induction was set to the IC 20 for cell proliferation inhibition. 34 Proliferation was quantified by Crystal Violet staining as described previously with minor modifications. 27 In brief, a 100 mL aliquot of each cell suspension at a concentration of 1×10 3 cells/mL for MDCKII, MDCKII-MDR1, MDCKII-BCRP, MDCKII-MRP1, MDCKII-MRP2 and MDCKII-MRP3 cells or a concentration of 3×10 5 cells/mL for LS180 cells was seeded onto collagen-coated 96-well microtitre plates and incubated for 24 h. The medium was replaced with drug-containing medium and the cells were incubated for a further 48 h. After incubation with test compounds, the cells were washed once with PBS and viable adherent cells were stained with 50 mL of 0.5% Crystal Violet (2.5 g of Crystal Violet in 20% methanol in sterile water) per well for 15 min. After staining, plates were washed with sterile water and dried for 4 h in a drying chamber at 378C or at room temperature for 12 h. To dissolve the Crystal Violet, 200 mL of methanol was added in each well. Absorption was measured at 555 nm excitation using a Multiskan RC photometer. Proliferation was expressed as the proliferation index, which was calculated as the absorption intensity of the test well in percentage points relative to zero proliferation (absorption of wells containing only medium set to 0%) and native proliferation (absorption intensity of untreated control cells set to 100%). Each experiment was performed at least in triplicate with n¼8 wells for each concentration.
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Induction assay
LS180 cells were seeded in 75 cm 2 culture flasks and incubated for 3 days. Cells were then treated with culture medium containing maraviroc (1 or 10 mmol/L), vicriviroc (1 or 10 mmol/L), raltegravir (1 or 10 mmol/L) and elvitegravir (1 or 10 mmol/L) in quadruplicate for 4 consecutive days (mRNA quantification and functional assay) or for 7 consecutive days (functional assay). Rifampicin 10 mmol/L served as a positive control and culture medium as a negative control. Cells were harvested, and a functional ABCB1 assay was performed and mRNA was isolated. Induction of ABC transporter mRNA expression was quantified by real-time RT-PCR. Induction of ABCB1 function was assessed by flow cytometric rhodamine 123 assay. For induction assays with maraviroc and elvitegravir, which were dissolved in DMSO, all incubation media, including the positive control and negative control (vehicle control), were supplemented with DMSO to reach an equal concentration of 0.1% DMSO in all solutions. In vicriviroc and raltegravir experiments (aqueous stock solutions) only the positive control (rifampicin) contained 0.01% DMSO, a concentration that has been shown to have no influence.
Functional assay for ABCB1 (rhodamine 123 efflux)
Induction of ABCB1 transport activity in LS180 cells was assessed by the flow cytometric rhodamine 123 efflux assay. In brief, cells (1×10 6 /sample) were incubated under light protection with the ABCB1 substrate rhodamine 123 (0.4 mmol/L) followed by an incubation with the specific ABCB1 inhibitor LY335979 (1 mmol/L) or with medium alone at 378C on a rotary shaker. Intermittent washing steps were performed at 48C with pre-cooled PBS (centrifugation for 5 min at 800 g). Intracellular fluorescence was quantified in an LSRII flow cytometer (Becton Dickinson, Heidelberg, Germany) with FACSDiva Software (Becton Dickinson, Heidelberg, Germany). In each sample, 30000 cells were analysed. Living cells were gated using forward versus side scatter. ABCB1 activity was determined as the ratio between the median fluorescence of LY335979 (1 mmol/L)-incubated cells (ABCB1 inhibited) and medium-incubated cells (not inhibited) normalized to the corresponding ratio of the negative control in the induction assays (without pretreatment with any drug). 25, 34 Quantification of mRNA expression by real-time RT-PCR RNA was isolated using the RNeasy Mini-Kit (Qiagen, Table 1 . The most suitable housekeeping gene for normalization in LS180 cells was identified using geNorm (version 3.4, Center for Medical Genetics, Ghent, Belgium), which determines the most stable reference genes from a set of tested genes in a given cDNA sample panel. 30, 35 Glucuronidase b (GU) proved to be the most stable housekeeping gene in LS180 cells under our experimental conditions. Data were evaluated by calibrator-normalized relative quantification with efficiency correction using the RelQuant software version 1.01 or LightCycler TM 480 software version 1.5 (Roche Applied Science, Mannheim, Germany) as described previously. 36 The software calculated the relative amount of the target gene and the reference gene (GU) based on the crossing points. Results were expressed as the target/reference ratio divided by the target/reference ratio of the calibrator. The results are therefore corrected for sample inhomogeneities and variance caused by detection. All samples were amplified at least in duplicate. 
Results
ABCB1 inhibition
Maraviroc showed no mdr1a/1b or ABCB1 inhibition up to the tested concentration of 50 mmol/L in P388/dx and 100 mmol/L in L-MDR1 cells and raltegravir also did not inhibit mdr1a/1b or ABCB1 at the maximum tested concentration of 50 mmol/L in P388/dx and 100 mmol/L in L-MDR1 cells. However, vicriviroc and elvitegravir clearly increased calcein fluorescence in P388dx and L-MDR1 cells, but not in the corresponding parental cell lines, which served as negative controls, indicating inhibition of ABCB1. Figure 1 shows one representative example of a calcein assay with vicriviroc and elvitegravir in P388/dx cells ( Figure 1a ) and L-MDR1 cells (Figure 1b) . The inhibitory potency was expressed as f2 values (Table 2 ).
ABCG2 inhibition
In the ABCG2 inhibition assay elvitegravir and vicriviroc increased PhA fluorescence in MDCKII-BCRP cells (Figure 2 ). Vicriviroc did not reach maximum effects up to the highest concentration tested (500 mmol/L). Therefore, the IC 50 value was estimated based on the maximum effect observed with the positive control FTC. Maraviroc and raltegravir increased PhA fluorescence in MDCKII-BCRP cells only minimally (data not shown), indicating only very weak ABCG2 inhibition. The data are summarized in Table 3 .
ABCC2 inhibition
The positive control MK571 reduced the transport of the fluorescent dye CDCF into the inside-out membrane vesicles overexpressing human ABCC2 with an IC 50 of 6.6+0.1 mmol/L (Figure 3 ). Maraviroc and vicriviroc, however, increased fluorescence, indicating increased transport of CDCF into the vesicles ( Figure 3 ). Raltegravir had no effects at all and for elvitegravir also no substantial effects were observed. Autofluorescence of the test compounds was not detected.
Proliferation assay
Proliferation assays in MDCKII cells and MDCKII cells overexpressing ABCB1, ABCG2, ABCC1, ABCC2 or ABCC3 were conducted to detect substrate characteristics. Significant differences in the resistance of MDCKII and MDCKII-MDR1 cells indicated that elvitegravir and vicriviroc are ABCB1 substrates (Table 4 ).
Calculation of the IC 50 values for raltegravir and maraviroc was not possible due to the low toxicity at the tested concentrations. However, cell proliferation in MDCKII parental, Induction of mRNA expression of drug transporters, PXR and relevant CYP enzymes in LS180 cells was analysed after 4 days of treatment with antiretrovirals. ABCB1 mRNA was significantly and strongly induced by elvitegravir at 1 and 10 mmol/L (Figure 4) . ABCC1 was only weakly induced by raltegravir (1.8+0.7 at 1 mmol/L and 2.0+0.6 at 10 mmol/L). ABCC3 was slightly induced by elvitegravir (1.9+0.5 at 1 mmol/L, P,0.05, and 2.0+1.0 at 10 mmol/L, P,0.05) and maraviroc (2.3+0.8 at 10 mmol/L, P,0.01).
The mRNA expression of ABCC2 and ABCC4 was not influenced by any compound tested. ABCG2 was weakly induced by elvitegravir (1.6+0.4 at 10 mmol/L, P,0.05) and maraviroc (1.7+0.4 at 1 mmol/L, P,0.05).
CYP3A4 mRNA expression was strongly induced by 10 mmol/L elvitegravir ( Figure 5) . None of the compounds tested induced Data are expressed as means+SD for three to six experiments with each concentration tested in octuplet. Statistical significance was evaluated using ANOVA with Dunnett's post hoc test compared with the untreated control. **P,0.01.
Novel antiretrovirals and drug transporters 807 JAC mRNA of PXR or CYP3A5 whereas CYP2B6 mRNA was significantly induced by elvitegravir (1.7+0.6 at 10 mmol/L, P,0.05). Among the SLCOs tested, only SLCO1B1 was significantly induced by 10 mmol/L elvitegravir (1.7+0.3 at 10 mmol/L, P,0.01).
For compounds with significant induction of ABCB1 mRNA expression at 10 mmol/L, induction was also quantified at the functional level after 3 days and 1 week of incubation. After 3 days of treatment, a trend towards increased ABCB1 activity was observed for rifampicin and elvitegravir ( Figure 6 ). After 7 days ABCB1 activity was significantly increased by elvitegravir, vicriviroc and the positive control, rifampicin ( Figure 6 ).
Discussion
Effective treatment of HIV-1 infections generally requires a combination of NNRTIs, NRTIs, PIs or the novel CCR5 antagonists and integrase inhibitors. Drug -drug interactions among antiretrovirals are frequent and are primarily mediated by modulation of activity and expression of CYPs, efflux and uptake transporters, leading to subtherapeutic or toxic concentrations, or the formation of sanctuary sites with reduced drug access. 37 Drug interactions may thus compromise the safety and effectiveness of HAART. However, data on the interaction potential of the CCR5 antagonists maraviroc and vicriviroc and the integrase inhibitors elvitegravir and raltegravir are sparse. We therefore investigated the interaction of these drugs with key transporters for HAART. Table 5 summarizes the most important findings.
Maraviroc is a known high-affinity ABCB1 substrate. 12 -14 Our study used proliferation assays for investigation of substrate characteristics. Although it has been demonstrated that proliferation assays are a suitable tool to detect substrates, 27 ,32,33 the low toxicity of maraviroc rendered it impossible to evaluate whether it is transported by ABCB1, ABCC1-3 or ABCG2. However, we verified that maraviroc is not an inhibitor of ABCB1 or ABCG2. Interestingly, maraviroc seems to stimulate ABCC2 transport. In contrast to the control inhibitor MK571, which decreased CDCF fluorescence in the inside-out vesicles, maraviroc increased fluorescence in a concentration-dependent manner. Autofluorescence as an underlying reason could also be ruled out, as unspecific access of CDCF to vesicles as fluorescence did not increase in the absence of ATP. It is thus possible that maraviroc activated ABCC2, as has been described for other drugs. 38, 39 A possible mechanism for the activation might be the existence of several binding sites of ABCC2, as proposed by Zelcer Zembruski et al.
et al. 40 If several binding sites 40 are involved, activation can be explained by allosteric binding of the test compound to a regulative site.
Clinically at least as important as the substrate or inhibitor properties of drugs are enzyme-and transporter-inducing characteristics, which may substantially increase the dose requirements of co-administered drugs and may result in nonresponse. Maraviroc did not induce CYP3A4, CYP3A5, CYP2B6 or most of the drug transporters tested. In contrast, maraviroc slightly induced ABCC3 and ABCG2 mRNA.
Taken together, these results indicate that the potential of maraviroc to influence the pharmacokinetics of co-administered drugs appears to be low as the effects observed in vitro were not very pronounced. So far, there are no clinical data corroborating the inhibitory or inducing properties of maraviroc, but no studies have been conducted that directly addressed this issue. However, we cannot rule out that ABCC2 activation leads to modulated distribution of ABCC2 substrates and that the induction of some of the transporters investigated might also modulate the disposition of other drugs.
The CCR5 inhibitor vicriviroc is still under development and its potential for interactions has not been investigated so far. Our study indicated for the first time that vicriviroc is an ABCB1 substrate, but not a substrate of ABCG2 or ABCC1-3. Moreover, our study demonstrated that vicriviroc inhibits ABCB1 with a potency similar to amprenavir and saquinavir 41 (Table 2 ) and also stimulates ABCC2 activity, as demonstrated for maraviroc (Figure 3 ). Plasma C max levels for vicriviroc have been reported to be in the range of 0.28 mmol/L on day 14 of vicriviroc 25 mg twice daily. 42 Plasma levels therefore are expected to be lower than concentrations necessary for ABCB1 inhibition or ABCC2 stimulation. The local concentration in the intestine, however, is probably substantially higher during dissolution of the formulation and subsequent drug absorption. 43 As the intestine is a major site of drug-drug interactions mediated by ABCB1, the pharmacokinetics of substrates of ABCB1 and possibly also of ABCC2 could be modulated. In contrast, the potential of vicriviroc to inhibit ABCG2 is most likely too weak to be clinically relevant. An induction assay showed that vicriviroc significantly increased ABCB1 function after 7 days of treatment (Figure 6 ), though the effect was not significant after 3 days at the mRNA level (Figure 4) . Moreover, vicriviroc did not induce the other tested transporters and CYP enzymes. The clinical relevance of ABCB1 induction is questionable, because vicriviroc has also been revealed to be an inhibitor of this transporter. Taking these results together, the interaction potential of vicriviroc at the level of drug transporters is presumably low, but so far clinical studies verifying this assumption are missing.
The results of the proliferation assays indicate that raltegravir is only transported by ABCB1. Concurrently, our results demonstrate that raltegravir does not inhibit ABCB1, which is in line with previous in vitro results. 17 Moreover, it does not inhibit ABCG2 or ABCC2. In the induction assay only ABCC1 expression was significantly induced by raltegravir (1.7-fold at 1 mmol/L and 2-fold at 10 mmol/L). C max plasma levels have been reported to be in the range of 1.3-5.3 mmol/L, 44 possibly resulting in potentially clinically relevant induction of ABCC1, at least in the intestine. Moreover, our data corroborate previously published data that raltegravir does not induce CYPs. 17 In summary, raltegravir appears to be the drug that is least prone to drug -drug interactions among the antiretrovirals tested in this study.
In contrast, the integrase inhibitor elvitegravir, which has not been approved yet, reveals, at least in vitro, a substantial interaction potential. Our data indicate that elvitegravir is transported by ABCB1 but not by the other ABC transporters tested. When co-administered with atazanavir/ritonavir or lopinavir/ritonavir, the area under the curve of elvitegravir was increased about 2-fold, 45 which might have been caused not only by CYP3A4 and UGT1A inhibition but also, at least partly, by ABCB1 inhibition.
Moreover, compared with the well-known and strong ABCB1 inhibitor quinidine, elvitegravir is an equipotent inhibitor (Table 2 ) and it also inhibits ABCG2 (Table 3) . Furthermore, our results demonstrate strong inducing properties for elvitegravir. It induced many transporters and all CYPs tested and for CYP3A4 and ABCB1 it was equipotent to the positive control, rifampicin, suggesting that it might cause clinically relevant drug -drug interactions with CYP3A4 or ABCB1 substrates. For ABCB1 we also confirmed induction at the functional level. In contrast to the mRNA induction, the increase in ABCB1 function needs a longer time period to become significant (Figure 6 ), because mRNA has to be translated into the protein and the latter has to be processed and integrated into the membrane before an effect becomes visible. Clinical data on drug -drug interactions with elvitegravir are sparse and there is no published study investigating the effect of long-term application of elvitegravir on the pharmacokinetics of CYP3A4 or ABCB1 substrates. Thus, no in vivo data exist corroborating the strong inducing effects observed in vitro. However, elvitegravir also revealed As demonstrated by studies published previously. 12 -14 Novel antiretrovirals and drug transporters strong inhibitory effects, which might be superimposed on induction. This might be the reason why elvitegravir has so far been reported to have a modest potential to be involved in clinically meaningful drug interactions. 45 However, there is one study demonstrating that the C max of the ABCB1 substrate maraviroc increased by factor 2.2 when co-administered with ritonavirboosted elvitgravir.
14 The authors hypothesized inhibition of CYP3A4 and ABCB1 by ritonavir, but inhibition of ABCB1 by elvitegravir also appears possible. Effective concentrations for ABCB1 inhibition in vitro match the reported C max levels found in clinical trials (1 -2.1 mmol/L depending on dosing scheme). 46 Thus, drug -drug interactions of elvitegravir with ABCB1 substrates could possibly be clinically relevant and require further attention in in vivo studies.
Some limitations of this study merit mentioning. We have analysed a selection of drug transporters and CYPs known to contribute to drug -drug interactions of antiretrovirals. Other transporters might also modulate the safety and effectiveness of therapy with these novel antiretrovirals. Furthermore, for all enzymes and transporters except ABCB1 we have quantified induction at the level of mRNA expression. Increased mRNA expression does not necessarily result in an augmented protein or activity level. It has, however, been shown that changes in mRNA expression are in the majority of cases associated with changes in the corresponding protein level 47 or altered function. 25,47 -49 Generally, LS180 cells as an induction model are most suitable for the investigation of induction mediated by the PXR. Because constitutive androstane receptor 1 (CAR1), which is expressed in hepatocytes, is apparently not expressed in LS180 cells, 26 it is a weak model for CAR1-mediated induction of transporters and CYPs, such as CYP2B6. 50 This study set out to determine the potential for drug -drug interactions of novel antiretrovirals. The evidence from this study suggests that clinically relevant drug -drug interactions of these novel antiretrovirals, especially elvitegravir, might occur, because elvitegravir modulates the expression of CYP3A4, ABCB1 and ABCG2 and the function of ABCB1 and ABCG2. At this point in time, data on drug interactions are sparse and it is therefore difficult to define those interactions that affect the safety and effectiveness of therapy. However, given the strong interaction potential of elvitegravir observed in vitro, our data should guide the design of drug -drug interactions studies with this compound in vivo.
